Group 1 - The core point of the article highlights that Microsoft CEO Satya Nadella's compensation for the fiscal year 2025 has surged to $96.5 million, marking the highest since he took on the role over a decade ago, attributed to significant advancements in AI [2] - Nadella's compensation increased by 22% compared to the fiscal year 2024, with a base salary of $2.5 million and 90% of his pay awarded in Microsoft stock [2] - The Microsoft Board of Directors stated that Nadella and his leadership team have positioned the company as a clear leader in the current technological transformation [2] Group 2 - Key executives at Microsoft also saw salary increases, with CFO Amy Hood's total compensation reaching $29.5 million and Judson Althoff's total compensation at $28.2 million following his recent promotion [5] - Microsoft's stock price has risen by 23% year-to-date, and the growth rate of its Azure cloud computing business continues to outpace competitors like Amazon [5]

格隆汇10月22日丨根据联交所最新权益披露资料显示，2025年10月16日，和铂医药-B(02142.HK)获GIC Private Limited在场内以每股均价13.5791港元增持69 万股，涉资约936.96万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | ( 請參閱上述 * 註 | 有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | (%) | | CS20251021E00017 | GIC Private Limited | 1101(L) | | 690,000(L | HKD 13.5791 | 62,975,000(L | 7.05(L)16/10/2025 | 增持后，GIC Private Limited最新持股数目为6297.5万股，持股比例由 ...

格隆汇10月22日丨信达生物(01801.HK)发布公告，2025年10月22日，信达生物与武田制药(透过武田制 药全资附属公司Takeda Pharmaceuticals International AG)达成全球战略合作，旨在加速推进信达生物新 一代IO及ADC疗法开发，拓展全球市场价值。本次合作包括两款后期在研疗法IBI363 (PD-1/IL-2)及 IBI343 (CLDN18.2ADC)，以及一款早期研发项目IBI3001 (EGFR/B7H3 ADC)的选择权。 根据合作，信达生物与武田制药将在全球范围内共同开发新一代IO基石疗法IBI363 (PD-1/IL-2)，并在美 国共同商业化，武田制药将在共同治理和协同一致的开发计划下主导相关工作；同时，信达生物授予武 田制药IBI363在除大中华区及美国地区的商业化权益。信达生物授予武田制药IBI343 (CLDN18.2ADC) 在大中华区以外地区的独家权益。此外，信达生物授予武田制药IBI3001(EGFR/B7H3 ADC)在大中华区 以外地区权益的独家选择权。 公司将获得12亿美元的首付款，包括以认购事项方式获得的1亿美元的战略股权投资，认 ...

通 讯 员 吴芸婷 本报讯 昨天上午，位于南湖区南湖新区（东栅街道）的嘉兴聚水潭智能科技有限公司所属的聚水潭集 团股份有限公司在港交所主板挂牌上市。此次上市标志着该公司发展进入新阶段。 （来源：南湖晚报） 转自：南湖晚报 N晚报记者 富玲燕 据悉，聚水潭此次全球发售6816.62万股，每股定价30.60港元，募集资金总额约20.86亿港元，净额达 19.38亿港元，主要用于技术研发升级与全球市场拓展。开盘后股价高开高走，涨幅超24%，报38.00港 元/股，总市值突破161亿港元。 "聚水潭在公司成立12年之际，成功在香港上市，对我们而言，是新的起点，更是新的挑战。"嘉兴聚水 潭智能科技有限公司创始人骆海东表示，未来，聚水潭将继续扩充产品矩阵，持续深化现有客户合作关 系并扩大客户规模，同时将进一步拓展国际市场，探索战略投资方向，以更加优质的产品反馈社会，以 更加卓越的业绩回报股东。 近年来，南湖新区（东栅街道）把抓好企业上市工作作为激发经济内生动力、促进经济转型升级、实现 高质量发展的重要举措，通过建立健全企业上市培育机制、服务网络和政策支持体系，不断优化资本市 场服务，助力企业股改上市，在更大范围、更广领域 ...

Core Viewpoint - Bubble Mart (09992.HK), referred to as the "Moutai for young people," reported a significant revenue increase of 245%-250% year-on-year for Q3 2025, yet its stock price fell by 8.08% to HKD 250.4 per share [2][7]. Revenue Growth - Overall revenue for Q3 2025 showed a year-on-year increase of 245%-250% [2]. - Revenue from China grew by 185%-190%, with offline channels increasing by 130%-135% and online channels by 300%-305% [4]. - International revenue surged by 365%-370%, with the Americas seeing a staggering increase of 1265%-1270% [4]. Global Expansion Strategy - The company has accelerated its globalization strategy, successfully entering key markets in Europe, Southeast Asia, Japan, and South Korea through localized operations and channel expansion [4]. - The number of overseas stores has increased, and online sales through cross-border e-commerce platforms have significantly risen [4]. Product Innovation and IP Management - Strong IP operation and product innovation capabilities have contributed to rapid revenue growth, with several new products becoming bestsellers [5]. - The "WHY SO SERIOUS" Halloween blind box series sold out within minutes, indicating high demand [5]. Market Concerns - Despite the impressive growth, there are concerns regarding the sustainability of IP monetization, as the market for collectible toys matures [7]. - Analysts suggest that reliance on blockbuster products may lead to revenue volatility, and the company needs a more diversified IP portfolio to mitigate risks [7]. Analyst Ratings - JPMorgan upgraded Bubble Mart's investment rating to "Overweight" and raised the target price from HKD 300 to HKD 320, anticipating significant sales and profit growth for 2025-2027 [8].

Li Thet因其决定投放更多时间于彼之其他承担及业务而辞任本公司、其附属公司及联营公司的执行董事 职务，自2025年10月21日起生效。据此，Li Thet自2025年10月21日起不再担任本公司的董事会主席及提 名委员会主席。 FSM HOLDINGS(01721)发布公告，其已获悉美国财政部外国资产控制办公室(外国资产控制办公室)于 2025年10月14日发布的新闻稿，其指定(其中包括)本公司执行董事Li Thet涉嫌参与太子集团跨国犯罪组 织的网络诈骗及洗钱活动而遭外国资产控制办公室实施制裁。 于获悉新闻稿后，本公司立即采取措施以确保全面遵守适用法律法规，并就此事对本公司可能构成的任 何潜在影响启动内部评估。本公司目前正寻求专业意见以评估及处理相关情况，并将于适当时候另行刊 发公告。 ...

劲方首席医学官汪裕博士表示："很高兴GFH375两项联合疗法方案进入临床阶段，尤其是一线PDAC治 疗将把GFH375临床开发从后线推向前线。GFH375单药治疗PDAC及非小细胞肺癌(NSCLC)的研究数 据，近期分别在ESMO和WCLC以突破性研究摘要、口头报告形式展示，优秀疗效提示了该产品治疗多 个瘤种的前景。我们期待基于该产品的多项国内外研究能够快速推进，早日造福患者。" Ib期试验将首先在北京大学肿瘤医院等约15家中心开展，整体试验的主要研究目的为评估GFH375联合 西妥昔单抗或化疗两项联合疗法在实体瘤患者中的安全性╱耐受性、疗效和药代动力学特征。II期试验 中，GFH375联合化疗（白蛋白紫杉醇和吉西他滨）方案将治疗一线晚期PDAC患者，GFH375联合西妥 昔单抗（EGFR单抗）方案将治疗晚期PDAC和结直肠癌(CRC)患者。 格隆汇10月22日丨劲方医药-B(02595.HK)宣布，GFH375联合疗法治疗KRAS G12D突变型晚期实体瘤的 Ib/II期研究首例患者在北京大学肿瘤医院完成入组。此项研究(GFH375X1202)于9月获得国家药品监督 管理局临床试验批准，该研究包含GFH37 ...

智通财经APP讯，劲方医药-B(02595)发布公告，GFH375联合疗法治疗KRAS G12D突变型晚期实体瘤的 Ib/II期研究首例患者在北京大学肿瘤医院完成入组。此项研究(GFH375X1202)于9月获得国家药品监督 管理局临床试验批准，该研究包含GFH375(口服KRAS G12D抑制剂)联合西妥昔单抗或化疗两项联合疗 法;其中GFH375联合化疗方案为一线胰腺导管腺癌(PDAC)治疗方案。 Ib期试验将首先在北京大学肿瘤医院等约15家中心开展，整体试验的主要研究目的为评估GFH375联合 西妥昔单抗或化疗两项联合疗法在实体瘤患者中的安全性╱耐受性、疗效和药代动力学特征。II期试验 中，GFH375联合化疗(白蛋白紫杉醇和吉西他滨)方案将治疗一线晚期PDAC患者，GFH375联合西妥昔 单抗(EGFR单抗)方案将治疗晚期PDAC和结直肠癌(CRC)患者。 GFH375单药疗法于2024年6月获国家药监局批准进入I/II期试验，GFH375/ VS-7375今年已获得FDA快速 通道资格认定，可用于一线及后线治疗局部晚期、转移性KRAS G12D突变型PDAC患者。 GFH375为口服高活性、高选择性 ...

Group 1 - Cainiao Guoguo has upgraded its "Double 11" services, expanding international shipping to over 60 countries, adding more than 40 new destinations [1] - The company has introduced a "2-hour pickup" service for merchants, significantly enhancing shipping efficiency during the peak sales period [1] - The logistics capabilities are crucial for e-commerce fulfillment, impacting promotional experiences and merchant competitiveness [1] Group 2 - Meituan Keeta is aggressively hiring, with high-paying positions available, including data analysts and senior algorithm experts, with salaries reaching up to 120,000 yuan annually [2] - Keeta, Meituan's overseas brand, is expanding its presence in high-potential markets such as Southeast Asia and the Middle East, where instant retail and delivery services are in demand [2] Group 3 - During the first hour of the 2025 Tmall "Double 11" sales, 80 brands achieved over 100 million yuan in sales, with 30,516 brands doubling their sales compared to last year [3] - The widespread adoption of "direct discount" models has lowered consumer decision-making barriers, while AI technology has improved demand-supply matching, enhancing conversion efficiency [3] - Leading categories in sales included beauty, sports, and consumer electronics, reflecting ongoing consumer demand for quality and the impact of new product launches and promotional strategies [3]

| 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | ( %) | | DA20251020E00561 | 噢噢您 | 1101(L) | | 520,000(L) | HKD 0.6746 | 274.947.736(L) | 16.90(L)20/10/2025 | 格隆汇10月22日丨根据联交所最新权益披露资料显示，2025年10月20日，VALA(02051.HK)获主席、行政总裁兼执行董事孙海涛在场内以每股均价0.6746港 元增持52万股，涉资约35.08万港元。 增持后，孙海涛最新持股数目为274,947,736股，持股比例由16.87%上升至16.90%。 | 股份代號: | 02051 | | ...